Strain 2 guinea-pigs were inoculated with infectious varicella-zoster virus (VZV) or with immunoaflinity-purified proteins of VZV. Monoclonal antibodies to the VZV gpI (90000/58 000 complex) and to a non-glycosylated protein, p170, were used to prepare the polypeptide antigens. Humoral and cell-mediated immune responses to the infectious virus were compared with those elicited by the gpI and p170 proteins. Both VZV IgG antibody production and T lymphocyte proliferation to VZV were detected after immunization with infectious VZV and with VZV proteins. The antibody and T lymphocyte responses waned after protein immunization in comparison with the responses induced by infectious VZV but were detected again immediately after reimmunization with gpI or p170.
infectious VZV were inoculated with 1 x l0 s to 1 x 106 VZV-infected cells subcutaneously as a single dose of 0.25 to 0-45 ml. The titration of these preparations by infectious centre assay was 1.0 x 104 to 1.6 x l0 s p.f.u./ml. The animals were inoculated in groups of four, with three animals receiving infectious VZV and one animal given the control preparation, by subcutaneous injection. Eighteen animals received infectious VZV with six controls. These animals were bled by cardiac puncture at 3 or 10 days after the initial injection, and at 3 weeks, 6 weeks and 12 and/or 18 weeks. A final sample was taken at 18 to 24 weeks from animals inoculated with infectious VZV and their controls.
VZV protein antigens were made by immunoaffinity separation as previously described, using a monoclonal antibody (MAb) to VZV gpI (90 000/58 000 Mr complex) and an antibody to p 170 which precipitated a protein of 170000 Mr and demonstrated a pattern of nuclear staining in VZV-infected cells (Arvin et al., 1986) . VZV-infected cell extracts were prepared from human melanoma cells labelled with [35S]methionine and detergent-solubilizect, lhe extract was ultracentrifuged and the supernatant was adsorbed to the MAb-coated Sepharose 4B overnight; bound proteins were eluted with 3 M-potassium thiocyanate pH 7.5. An uninfected cell control preparation was made in parallel. Each preparation was examined by SDS-PAGE and autoradiography or by immunoblot; densitometric tracing showed that the VZV-specific bands made up at least 72 % of the protein preparations. Animals receiving VZV protein antigens and their controls were given an initial inoculation followed by a second injection at 1 week, with the bleeding schedule as described for animals given infectious VZV started after the second dose. A third injection was given to these animals at 6 or 18 weeks. Each injection contained 50 ~tg protein in phosphate-buffered saline. The animals were inoculated in groups of four, with three animals receiving the VZV protein antigen and one animal given the corresponding control preparation, by subcutaneous injection. Fifteen animals were given gpI with five controls, and 12 animals were given p 170 with four controls. The morbidity associated with cardiac puncture prevented some samples from being obtained and led to the death of some animals, especially at the early time points when the animals were small.
The acquisition of humoral immunity to VZV as measured by radioimmunoassay (RIA) (Arvin & Koropchak, 1980) of sera from animals given a single inoculation of guinea-pigadapted VZV and those given an initial injection of VZV protein antigen, gpI or p 170, followed by a second dose after 1 week and a third dose at 6 or 18 weeks is shown in Fig. 1 . Specific binding of VZV IgG antibodies was detected using 125i_labelled monospecific goat antiserum to guinea-pig IgG (Cappel Laboratories). The antibody titre was read as the serum dilution where the ratio of mean c.p.m, of duplicate antigen wells to mean c.p.m, of duplicate control wells was above 2-5. Four of eight animals had detectable antibody to gpI by 10 days after the first injection as did four of seven animals given p 170, whereas all of nine animals tested 10 days after inoculation with infectious VZV remained seronegative. However, all of the animals given infectious VZV showed seroconversion by 3 to 6 weeks and 18 of 21 samples taken from 12 to 18 weeks after inoculation had VZV antibody titres of/> 1:16. The geometric mean titre (GMT) did not differ for animals in the groups given 1 x l0 s to 6 x l0 s infected cells/dose compared with those given 1 × 10 6 infected cells/dose. The GMT of sera from animals tested 12 to 18 weeks after inoculation with infectious VZV was 1 : 100 with seven of nine animals showing persistent antibody >~ 1:16, while the GMT in animals given gpI and p170 declined to ~< 1 : 16 during the same interval. When animals in the latter group received a third injection of the respective protein preparation, the antibody titres rose rapidly to high values, with the GMT at 3 weeks being 1:8709 for gpI and 1:7943 for p170. The titres were < 1:16 by RIA in all of the sequential serum samples obtained from the six control animals given the uninfected cell preparation and in the four animals from each group given gpI or p170 control preparations.
Two serum samples which showed titres /> 1 : 1024 by RIA following injection with glbI or p170 were tested by immunoblot to demonstrate serum antibodies reactive with specific VZV proteins. Immunoaffinity-purified VZV proteins and the control preparations made with each MAb were separated by SDS-PAGE in a 9% acrylamide gel cross-linked with methylenebisacrylamide followed by electrophoretic transfer to nitrocellulose with a Trans-Blot chamber (Bio-Rad). The nitrocellulose strips were incubated with the test sera at a dilution of 1 : 20. The binding of IgG in the test serum was detected by immunoperoxidase stain using biotinylated goat antibody to guinea-pig IgG, an avidin-biotin complex solution (Vectastain ABC kit; Vector Laboratories, Burlingame, Ca., U.S.A.) and 4-chloro-l-naphthol. The Mr of visible bands was estimated using reference standards. Sera from animals that had been inoculated with uninfected guinea-pig embryo cells were included as controls. In each case, IgG binding was detected to proteins of the expected Mr based upon the protein complex which had been used for immunization, whereas no reactivity was present against the other protein preparation.
Short communication
Antibody binding to specific proteins was also demonstrated by using the MAbs in a solid phase RIA to capture the VZV protein (Arvin et al., 1986) . The blocking of antibody binding to the specific VZV protein antigen was demonstrated in these sera when the homologous MAb was added to the plates before the test serum; the titres were reduced to < 1:16 by capture RIA. Sera were tested for VZV-neutralizing antibodies in a plaque reduction assay by incubating the heat-inactivated test serum with a standard inoculum of 500 p.f.u./ml of VZV (50 p.f.u,/well), with and without guinea-pig complement (Hazelton Biotechnologies, Vienna, Va., U.S.A.), used at an initial dilution of 1:8. The sample was added to a freshly confluent monolayer of Vero cells in 24-well tissue culture plates, and overlaid with MEM containing 10~o foetal calf serum. Plaques were counted after 10 to 14 days incubation after staining with crystal violet. The neutralization endpoint was read as the serum dilution producing 50~o plaque reduction compared to control wells containing serum from an animal injected with an equivalent number of uninfected guinea-pig embryo cells. Complement-dependent neutralizing antibody against VZV, with titres of 1:16 to 1:64, was detected as late as 12 weeks in five animals tested after the initial injection of gpI. The neutralizing titres with complement rose to 1:128 in two animals tested 10 days and 3 weeks, respectively, after the third injection of gpI. Five animals given infectious VZV had low titres of complement-independent neutralizing antibodies (1 : 8 to 1 : 16) which were enhanced to 1 : 16 to 1 : 64 by complement; these antibodies persisted for 6 to 12 weeks. None of six animals given p170 had VZV-neutralizing antibodies at 3 to 6 weeks after the initial injection of p170 or after subsequent p170 injections.
VZV-specific, cell-mediated immunity was measured with a T lymphocyte proliferation assay in vitro by incubating peripheral blood mononuclear cells, obtained by cardiac puncture and separated with Ficoll-Hypaque, with VZV antigen or an uninfected cell control in 96-well microtitre plates. The cells were cultured at a concentration of 2 x 105 cells/0.1 ml per well in RPMI with 10 ~ guinea-pig serum, 2-r~ercaptoethanol and 5 ~ NaHCO3. Duplicate wells were incubated with antigen or control at 1:4, 1:16 and 1:64. After 5 days, the wells were pulselabelled with [3H]thymidine. On day 6, the cells were harvested onto glass filter paper and radioactivity was counted in a liquid scintillation counter. The stimulation index (S.I.) was calculated as the ratio of mean c.p.m, in duplicate antigen-stimulated wells to the mean c.p.m, in duplicate uninfected cell control wells. Each assay included control wells stimulated with phytohaemagglutinin. As shown in Fig. 2 , the injection of guinea-pigs with VZV gpI and VZV p170 elicited lymphocyte proliferation to VZV antigen with the peak stimulation index (S.I.) detected at 3 weeks after the initial inoculation. The mean peak S.I. was 5.2 + 1.03 s.~. for gpI and 6-6 + 1.53 s.E. for p170. The mean S.I. for 17 samples from gpI control animals w.as 1-25 + 0.16 s.~. and for 11 samples from p 170 controls was 0.94 + 0.13 s.E. The peak S.I. did not occur until 6 weeks after inoculation of the animals with infectious VZV but it rose to 8-7 + 2-05 S.E. The mean lymphocyte proliferation response decreased to less than 2.0 by 12 weeks after immunization with gpI and p170 whereas six of eight guinea-pigs tested 18 to 24 weeks after inoculation of infectious VZV maintained S.I. above 2-0. As was observed in the analysis of the humoral immune response, the third dose of gpI and p170 produced an immediate rise in cellmediated immunity as determined by lymphocyte proliferation (Fig. 2) .
Most animals that had S.I. >/2.0 after injection with gpI or p170 also had humoral immunity when both responses were tested on the same blood sample. Six of seven animals with S.I. 1> 2.0 after gpI also had VZV antibody titres >/1 : 16 as did five of six animals given p170.
These studies demonstrated that gpI and pt70 were equally immunogenic in inducing both humoral and cellular immunity in the strain 2 guinea-pig. Herpesvirus glycoproteins have been considered likely to be important in producing virus-specific immunity because of their expression on the membranes of infected cells and because MAbs to the surface glycoproteins of human herpesviruses often have neutralizing activity (Keller et al., 1984; Friedrichs & Grose, 1984; Rasmussen et al., 1985) . Immunization with the gpI protein prepared by immunoaffinity using a gpI reactive MAb also elicited a neutralizing antibody response in vivo that was complement-dependent, as was observed by Keller et al. (1986) . Although p170 did not elicit neutralizing antibody in vivo, it induced both IgG antibody and T lymphocyte proliferation in the strain 2 guinea-pig which parallels our observation of persistent humoral and cellular immunity to p170 in most human subjects following VZV infection (Arvin et al., 1986 ). The emphasis upon glycoproteins in viral immunology may require modification given the evidence of host responses to the non-glycosylated, internal or nucleoproteins of several other viruses (Townsend et al., 1984; Yewdell et al., 1986) . The induction of both humoral and cellular immunity in the strain 2 guinea-pig following immunization with VZV proteins is consistent with the demonstration of both antibody and T lymphocyte proliferation to herpes simplex virus and cytomegalovirus proteins in murine and guinea-pig models (Donnenberg et al., 1980; Shrier et al., 1983; Bia et al., 1983; Gonczol et aL, 1986) . These observations contradict the concept that purified viral proteins are likely to induce only humoral immunity. However, the waning of VZV antibodies and T lymphocyte proliferation illustrates the general failure of immunization with herpesvirus proteins to induce long term immunity. Both peak IgG antibody production and T lymphocyte proliferation responses were delayed in animals given infectious VZV in comparison with those of animals given gpI and p 170. This delay suggested that a phase of viral replication in vivo occurred which, by analogy with the experience with live viral vaccines, may be essential to elicit persistent immunity. One hypothesis is that local viral replication or replication in the regional lymph nodes provides a critical opportunity for antigen presentation to an essential T lymphocyte subpopulation. Nevertheless, despite the waning of VZV immunity after protein injection, our studies demonstrated a 'priming' effect upon the immune response to the third injection of gpI or p170. This phenomenon, as initially described with poliovirus peptides (Emini et al., 1983) , warrants further investigation in relation to the development of subunit herpesvirus vaccines.
Although a live attenuated varicella virus vaccine has been effective in selected populations, the live virus vaccine causes cutaneous lesions in some patients, suggesting the occurrence of viraemia (Gershon et al., 1984) . The vaccine virus can also establish latent infection, making it less desirable for use in the general population in which much of the morbidity caused by VZV is due to the reactivation of latent virus. The investigation of the immune response to VZV proteins in the guinea-pig provides background for testing methods of enhancing the immunogenicity of purified viral proteins (Ho et al., 1986) which can then be compared to the immune response to infectious VZV.
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